Potent and selective CB2
receptor partial agonist (EC50
= 0.65 nM; maximum inhibition = 44.6%). Binds with high affinity to both human and rat CB2
receptors and displays ~ 1200-fold selectivity over CB1
values are 3.92 and 4772 nM for human recombinant CB2
receptors respectively). Produces potent antihyperalgesic effects in several rodent models of pain.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.
Clayton et al.
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano et al.
The citations listed below are publications that use Tocris products. Selected citations for GW 405833 include:
Showing Results 1 - 2 of 2